Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
This acquisition enables MTD to open new, strategic markets
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Combination shows consistent benefit across prespecified post-progression outcomes
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Subscribe To Our Newsletter & Stay Updated
